RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. It inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM, respectively. It also acts as a c-Met kinase inhibitor with an IC50 of 1.1 μM. In vitro, RIPK3-IN-1 also inhibits ABL, BRAF/V599E, MAP4K3, and SRC with IC50s of 0.37, 0.15, 0.012, and 0.075 μM, respectively.
- Inhibits RIPK3 with high potency
- Targets RIPK1 and RIPK2
- Acts as a c-Met kinase inhibitor
- Exhibits additional inhibitory activity against ABL, BRAF/V599E, MAP4K3, and SRC
- Useful for studying necroptosis, a programmed form of cell death
- Relevant for research into various diseases including ischemia reperfusion injury, neurodegenerative disorders, pancreatic cancer, and autoimmune diseases like inflammatory bowel disease (IBD)